4/24/2024
Molecular
BRAF Mutation Analysis by PCR - This test is now available for New York state orders as of Monday, April 22nd!
This assay is designed to detect V600 mutations E, K, D, R, and G. BRAF mutations are found in several cancer types including melanoma, papillary thyroid, colorectal cancer, and non-small cell lung cancer (NSCLC). For more test details and specimen requirements, please visit the test menu page.
Molecular Specimen Hold Services – As of Monday April 15th, the following updates have been implemented.
- Discontinuation:
- Freeze & Hold option has been discontinued. Please select one of the Extract & Hold options listed below as a replacement.
- Expansion:
- Extract & Hold option are now available as follows. Options can be ordered individually or concurrently, if desired
- Extract & Hold – DNA: DNA will be isolated from viable cells and stored in freezer. Select this option if possible test to be ordered is DNA-based. Examples: FLT3 Mutation Analysis, IDH1/IDH2 Mutation Analysis by PCR
- Extract & Hold – RNA: RNA will be isolated from viable cells and stored in freezer. Select this option if possible test to be ordered is RNA-based. Examples: IgVH Mutation Analysis, PML-RARA Translocation t(15;17)
- Extract & Hold – TNA: Total nucleic acid (TNA), i.e. both DNA and RNA, will be isolated from viable cells and stored in freezer. Select this option if possible test to be ordered is TNA-based. Examples: NGS assays, such as Neo Comprehensive and NeoTYPE profiles.
- Analysis is not performed until testing is ordered. Processed samples are retained for 28 days.
- Charges will be waived when testing is ordered on held specimens. Otherwise, a fee will be billed to client for each extraction option that is ordered. For pricing information, please contact your local NeoGenomics sales rep or Client Services at 866.776.5907, option 3.
- Now Available! We now have a webpage that lists all tests available for each aforementioned Extract & Hold options to assist with the ordering of the service: Extract and Hold Service, Hematologic Disorders.
Requisition Updates
New versions of the Heme test requisition forms, aligning with recent test and service updates, are available for download on our website and for orders with our Client Services team.
- Hematopathology Requisition – version 031324
- Oncology Office Hematology Requisition – version 021624
- New York State Hematopathology Requisition – version 031424
- New York State Oncology Office Hematology Requisition – version 031424
Additional Updates
FOLR1 Ovarian Cancer Testing Program
NeoGenomics Laboratories and our partnership with ImmunoGen, Inc. continues to offer the FOLR1 testing program which provides testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients.
Approximately 35% of ovarian cancer patients are expected to be positive for folate receptor alpha (FRα)1, meaning over a third of people with advanced ovarian cancer may have a different treatment option.
Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy.
To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit our website.
For a complete list of interface-related test changes, click here for a downloadable document to view the impacted interface test codes.